Professional Practice Advisories
Professional Practice Advisories are developed by AMCP and approved by the Board of Directors. These Member Only advisories provide an in-depth look for the pharmacist member on the issues that are at the forefront of managed care pharmacy today.
Professional Practice Advisory on Brown Bagging
Pharmacists need to understand the risks and benefits of brown bagging medications in order to make informed decisions on the appropriateness of a brown bagging program.
Professional Practice Advisory on Collaborative Drug Therapy Management (CDTM)
Collaborative drug therapy management (CDTM) is a formal partnership between a pharmacist and physician or group of pharmacists and physicians to allow the pharmacist(s) to manage a patient's drug therapy.
Professional Practice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits
Practice Advisory on Drug Coverage Parity presents issues that arise when contemplating benefit design drug coverage parity issues.
Professional Practice Advisory on Factors to Consider in Management of Specialty Pharmaceuticals
This practice advisory identifies several different ways to manage specialty drugs and many questions that should be answered when evaluating specialty drug benefits.
Professional Practice Advisory on Opioid Therapy Management
This practice advisory identifies strategies used by Managed Care Organization, federal and local governments and the pharmaceutical industry to manage Opioid therapy.
Professional Practice Advisory on Tablet Splitting
Professional Practice Advisory on Tablet Splitting address concerns of managed health care systems and guidelines that should be in place to determine which medications may be appropriate for tablet splitting.
Professional Practice Advisory on the Impact of the Genetic Information Nondiscrimination Act of 2008
Practice Advisory on the Impact of GINA to Managed Care Pharmacy identify many questions that have arisen about the implications of GINA on the practice of managed care pharmacy.
Professional Practice Advisory on Unapproved Medications
Prescription and over-the-counter (OTC) drug manufacturers are required to complete the Food and Drug Administration’s (FDA) approval process prior to marketing; however, for various reasons, there are currently medications marketed, prescribed and dispensed without this approval.